Swarm Learning Team
TitleNamePositionContact Dr. Anna Aschenbrenner Group Leader Anna.Aschenbrenner@dzne.de +49 228 43302 690 M. Sc. Jesse Asimeng PhD candidate…
** The Free State of Saxony requests the disclosure of the following information: “This measure is cofinanced by tax revenue based on the budget passed by the Saxon…
DZNE participating in European Research Initiative on Alzheimer’s
Bonn (Germany), January 13, 2026. DZNE is set to receive about €1 million in funding as part of an international consortium of…
back to overview
in cooperation with
AMBLIND
General
To investigate the causes and consequences of aphantasia, aphantasists as well as unaffected control subjects are recruited.
Background…
DZNE Local principal investigator: Dr. Axel Lipp Local contact: Janine Bieck +49 30 450660-359 Mandy Schickor +49 30 450660-478
DZNE Local principal investigator: Prof. Dr.…
back to overview
REALISE
General
The early detection of Alzheimer's disease using biomarkers is a prerequisite for the use of new antibody therapies in the treatment of the disease, which have…
DZNE Universitätsklinikum Bonn - Klinik für Alterspsychiatrie und Kognitive Störungen Local principal investigator: Prof. Dr. Anja Schneider
DZNE Universitätsklinikum TU…
back to overview
TAK-341-2001
A Study of TAK-341 in Treatment of Multiple System Atrophy
To get more information, please go to msa-clinicalstudy.com
See also the information on…
back to overview
CNIO752A02101
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy
Approved information available in German only:…
back to overview
ANQUR
The primary objective of this study is to determine the safety and tolerability of multiple doses of QRL-201 in people living with ALS.
This first-in-human, Phase 1 study…
